This is a preview of subscription content, log in via an institution to check access.
References
Benson CA, Cohn DL, Williams P, et al. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA + RBT for prevention of Mycobacterium avium complex disease in HIV+ patients with CD4+ counts ≤ 100 cells/μL (abstract no. 205). 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28–Feb 1: Washington: 91
Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomised, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905–12
Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifampin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377–83
May T, Brel F, Beuscert C, et al. A French randomised open trial of 2 clarithromycin combination therapies for MAC bacteremia: first results [abstract LB-19]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17–20: San Francisco
Burman W, Reves R, Rietmeijer C, et al. Relapse of disseminated Mycobacterium avium complex disease and emergence of resistance to clarithromycin despite treatment with a multi-drug regimen [abstract 176]. 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28–Feb 2: Washington
Rights and permissions
About this article
Cite this article
Round-Table Discussion. Drugs 54 (Suppl 2), 28–29 (1997). https://doi.org/10.2165/00003495-199700542-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199700542-00007